GNNSF

$3.21-$0.03 (-0.93%)live

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

52-week range

$1.30 – $3.30

96% from low

Exchange

OTC Link

Change$-0.79

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$842M	-11.4%	$0.02	$0.02–$0.02	167.1×	1
2027	$988M	+17.4%	$0.05	$0.04–$0.05	66.7×	1
2028	$1.1B	+15.6%	$0.09	$0.08–$0.10	37.0×	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Beat consensus in 2 of the last 5 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-03-15	$-0.03	$-0.23	-666.7%
2025-08-17	$0.08	$-0.02	-127.0%
2025-03-11	$-0.01	$1.48	+14900.0%
2024-08-09	$-0.01	$-0.08	-727.0%
2024-03-10	$-0.05	$-0.03	+36.0%

Symbol	Price	Today	Mkt cap	P/E
GNNSFGenscript Biotech Corporation	$3.21	-0.93%	$7.0B	—
AKBLFALK-Abelló A/S	$37.91	+0.00%	$7.6B	—
CAMRFCamurus AB	$64.00	+9.38%	$3.8B	—
CZMWFCarl Zeiss Meditec AG	$33.63	-3.80%	$2.9B	—
INCPFInnoCare Pharma Limited	$1.55	+0.00%

No one on the platform currently holds GNNSF.

Institutions holding (13F)

No tracked institution reports a position in GNNSF as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

No one on the platform has traded GNNSF yet.